Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company
This article was originally published in Scrip
Shire plc and Baxalta Incorporated have confirmed they are to merge. The combined company, which will be 34% owned by Baxalta shareholders, will be "the partner of choice in rare diseases," claimed Shire CEO Flemming Ornskov.
Register for our free email digests: